Filing Flows › Onconetix (ONCO) › Q4 2025
Onconetix (ONCO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 13, 2026
Onconetix (ONCO) reported revenue of $304K for the fourth quarter 2025 (Q4 2025), -57% from a year earlier and 0% from the quarter before. Operating margin was -422.1%.
Onconetix, Q4 2025: revenue $304K (-57% year over year), operating margin -422.1%, net earnings $5.7M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $304K | 0% | -57% |
| Operating profit | −$1.3M | — | — |
| Net earnings | $5.7M | — | — |
| Operating cash flow | −$3.1M | — | — |
What changed
Revenue was $304K in Q4 2025, down 57% year over year and roughly flat from the previous quarter.
Gross margin was 81.6%, down 11.1 points from Q4 2024. Operating costs exceeded revenue by $1.3M, an operating margin of -422.1%. Operating expenses fell 95% while revenue fell 57%. Net earnings were $5.7M. The effective tax rate was 0.0%. Non-operating items added $7.0M, 123% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.1M. Non-cash charges added back $3K of depreciation and amortization and $4K of share-based compensation. Working capital and other items used $8.8M.
Questions
What was Onconetix's revenue in the fourth quarter 2025?
Onconetix (ONCO) reported revenue of $304K for the fourth quarter 2025 (Q4 2025), -57% from a year earlier and 0% from the quarter before.
Was Onconetix profitable in the fourth quarter 2025?
Operating loss was $1.3M (-422.1% of revenue) and net earnings $5.7M.
Source: Onconetix 10-K on SEC EDGAR.